Whole exome analysis reveals the genomic profiling related to chemo‐resistance in Chinese population with limited‐disease small cell lung cancer. (23rd June 2022)

• Record Type: Journal Article
• Authors: Yu, Jiangyong; Zhao, Shuangtao; Su, Zhe; Song, Chengli; Wu, Lihong; Wang, Jingbo; Bi, Nan; Wang, Lvhua
• Is Part Of: Cancer medicine. Volume 12:Number 2(2023)
• Page Start: 1035
• Page End: 1050
• Publication Date: 2022-06-23
• Subjects: chemotherapy resistance -- neo‐adjuvant therapy -- small cell lung cancer -- whole exome sequencing; 616.994005
• DOI: 10.1002/cam4.4950
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Purpose: The mechanism of chemo‐resistance in small cell lung cancer (SCLC) is unclear. This study aims to explore the resistance‐related genomic profiles of residual tumors after neo‐adjuvant chemotherapy (NAC) in SCLC through the whole‐exome sequencing (WES). Experimental design: A total of 416 limited diseases (LD) SCLC patients underwent surgery were retrospectively analyzed, of which 40 patients received NAC. Then we selected 29 patients undergoing NAC ( n = 19) and chemotherapy naïve (CTN, n = 10) to perform WES sequence with formalin‐fixed paraffin‐embedded samples including tumor and paired para‐tumor. Results: In total, single nucleotide variation and mutation rate were similar between NAC and CTN groups. The mutation signatures were significantly discrepant between NAC and CTN groups, as well as among patients with partial response (PR), stable disease (SD), and progressive disease. There were more copy number variation deletions in NAC group compared with CTN group. The inactivation of TP53 and RB1 were the most significantly events in both NAC and CTN groups. RB1 nonsense mutations were recurrent in NAC group (9/19 vs. 0/9, 47.4% vs. 0%) with favorable survival, while the frame‐shift deletions were frequent in CTN group (3/9 vs. 3/19, 33.3% vs.15.8%). Integrated function enrichment revealed that the frequently mutant genes were involved in cell cycle, metabolic reprogramming, and oncogenic signaling pathways in NAC group, such as BTG2 pathway, glycolysis in senescence and P53 pathway. A total of 27 genes presented frequently mutant in NAC group and might played a positive role in drug resistance. Multiple genes including BRINP3, MYH6, ST18, and PCHD15, which were associated with prognosis, occurred mutant frequently in PR and SD groups. Conclusion: Residual tumors after neo‐adjuvant therapy exhibited different mutation signature spectrum. Multiple genes including RB1 nonsense mutations, BRINP3, MYH6, ST18, and PCHD15 were with frequent mutation in residual tumors, which might participate chemo‐resistance and influenced the prognosis in patients with limited disease SCLC. Abstract : Genomic alterations related to chemo‐resistance in small cell lung cancer.